---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-004387"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2023-02-24T23:59:59+00:00"
generated_at: "2026-06-19T01:11:53.007640+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma reports FY2022 net loss of $9.9M; cash $42.4M; strategic review ongoing

## Summary
- Net loss $9.9M ($0.69/share) vs $19.3M ($1.39/share) in 2021; operating expenses down to $10.6M from $19.3M.
- Cash and equivalents $42.4M at year-end; expected to fund operations through mid-2024.
- R&D expenses fell to $4.7M from $13.8M due to completion of rNAPc2 Phase 2b trial; restructuring charges of $0.8M in Q3 2022.
- Company engaged Ladenburg Thalmann to explore strategic alternatives including M&A; no timetable set.

## SEC filing metadata
- accession: 0000950170-23-004387
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2023-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000095017023004387/0000950170-23-004387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000095017023004387/abio-20230224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-004387
- JSON: https://secwatch.observer/filing/0000950170-23-004387.json
- Plain text: https://secwatch.observer/filing/0000950170-23-004387.txt

## Key facts
- Earnings Releases
  Oruka Therapeutics, Inc. reported the year ended December 31, 2022 results: net income $9.9 million, EPS $0.69 per basic and diluted share.
  - Period: the year ended December 31, 2022
  - Net income: $9.9 million
  - EPS: $0.69 per basic and diluted share
  - Result: reported results
  source text: Net loss for the year ended December 31, 2022 was $9.9 million, or $0.69 per basic and diluted share, compared to $19.3 million, or $1.39 per basic and diluted share in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000095017023004387/0000950170-23-004387-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.